大行評級|交銀國際:下調先聲藥業目標價至10港元 但維持“買入”評級
交銀國際發表報吿,稱先聲藥業上半年收入按年下跌7.9%,符合此前業績預吿區間,管理層預計公司全年收入將按年保持穩定或有輕微增長,預計經調整淨利潤將有逾三成的增長,毛利率未來將保持在約80%,全年派息率穩定在30至60%。
交銀國際維持先聲藥業“買入”評級,目標價降至10港元,認為公司業績增長能見度高,預計2024至2026年收入及經調整淨利潤複合年均增長率有望達到14%及21% ,主要受惠於先必新循證醫學證據、指南推薦級別及醫院覆蓋不斷加強;抗腫瘤藥科賽拉將全力參與年底醫保談判,若能取得成功,預計年銷售將快速升至5億元以上;而未來18個月公司還將上市蘇維西塔單抗及達利雷生,合計最高銷售或有望超30億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.